<![CDATA[Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?]]>

ConferenceiberdomideCAR T cellsbispecific antibodiesNeutral

AI Analysis

Summary

Expert discussion on how CELMoDs like iberdomide could complement CAR T cell and bispecific antibody therapies in multiple myeloma treatment paradigm.

Importance:2/10

Sentiment:

0.00

multiple myelomaCELMoDsimmunotherapycombination therapyexpert discussion

Related Companies

$CELG

Read the original article

Published by Cancer Network on August 27, 2026 12:00 PM

Read Original